自然杀伤细胞在卵巢癌免疫治疗中的研究现状及展望OA

Ovarian cancer remains the most lethal gynecologic malignancy.Although cytoreductive surgery and platinum-paclitaxel combination chemotherapy as first-line treatment have improved outcomes for a subset of patients,the majority eventually develop platinum-resistant recurrence,underscoring the urgent need for novel therapeutic strategies to achieve durable disease control.Recent advances in natural killer(NK)cell-based immunotherapy have demonstrated substantial potential for ovarian cancer treatment,capitalizing on the potent cytotoxicity and favorable safety profile of NK cells.This review systematically discusses how the ovarian cancer tumor microenvironment(TME)impairs NK-cell function through enrichment of inhibitory cytokines,metabolic reprogramming,and overexpression of inhibitory immune checkpoints on the NK-cell surface.It then focuses on current therapeutic strategies and their clinical development,including cytokine-based therapies,chimeric antigen receptor-NK(CAR-NK)cells and NK cell engagers(NKCEs).We further summarize the landscape of completed and ongoing clinical trials involving NK-cell-based immunotherapy for ovarian cancer,and discuss future directions for rational combination strategies,so as to provide updated insights to optimize NK cell-based immunotherapeutic approaches.